和铂医药签订独家授权协议
财中社1月12日电和铂医药（02142）发布公告，宣布与四川科伦博泰生物医药股份有限公司及Windward Bio AG签订了HBM9378/SKB378的独家授权协议。根据协议，授权方将授予Windward Bio全球独家许可，以在大中华区及若干东南亚和西亚国家以外生产、开发、使用、推广、销售、许诺销售、进口及以其他方式商业化HBM9378/SKB378。
根据协议，授权方有权收取最多合计9.7亿美元的预付款和里程碑付款及占净售额个位数到双位数百分比的分层特许权使用费。该协议的签订预计将有助于整合授权方与Windward Bio的研发、生产和商业化能力，将HBM9378/SKB378推向全球市场。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10